Catalyst Pharmaceuticals

Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, March 5, 2024

CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming Barclays 26th Annual Global Healthcare Conference being held in Miami on March 12-14, 2024.

Key Points: 
  • CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming Barclays 26th Annual Global Healthcare Conference being held in Miami on March 12-14, 2024.
  • Format: Catalyst's management will host 1x1 meetings and a fireside discussion at 1:35 pm ET.
  • A live webcast of the fireside will be available on the Company's website , and a replay will be accessible for at least 14 days.

Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE

Retrieved on: 
Tuesday, February 27, 2024

The poster will detail the establishment of a multicenter, observational, prospective, longitudinal registry at approximately 25 U.S. sites.

Key Points: 
  • The poster will detail the establishment of a multicenter, observational, prospective, longitudinal registry at approximately 25 U.S. sites.
  • Investigators will assess the progress of 250 male patients who are at least 2 years old at week 12 and then every 12 months for up to five years.
  • The first interim analysis is expected in May 2025.
  • "We encourage physicians treating patients with DMD to consider enrolling eligible patients in this registry."

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

Retrieved on: 
Wednesday, February 21, 2024

Catalyst holds the exclusive rights to commercialize AGAMREE® (vamorolone) in North America.

Key Points: 
  • Catalyst holds the exclusive rights to commercialize AGAMREE® (vamorolone) in North America.
  • Based on the published study, Santhera has reported that the results of the VISION-DMD study support the long-term efficacy and safety profile of vamorolone and conclude that vamorolone was generally well tolerated, consistent with the 24-week study findings, as published previously in JAMA Neurology [2].
  • This study [VISION-DMD] was conducted to determine the efficacy and safety of vamorolone over 48 weeks and to study crossover participants (prednisone to vamorolone; placebo to vamorolone).
  • Improvements of motor outcomes seen with 6 mg/kg/d of vamorolone at 24 weeks of treatment were maintained to 48 weeks of treatment.

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

Retrieved on: 
Wednesday, February 14, 2024

CORAL GABLES, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release its fourth quarter and full-year 2023 financial results after the market close on February 28, 2024.

Key Points: 
  • CORAL GABLES, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release its fourth quarter and full-year 2023 financial results after the market close on February 28, 2024.
  • Catalyst's management team will host a conference call and webcast the following morning, Thursday, February 29, 2024, at 8:30 AM ET, to discuss the Company's financial results and provide a business update.

Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering

Retrieved on: 
Tuesday, January 9, 2024

CORAL GABLES, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) today reported that it has closed its underwritten public offering of shares of its common stock.

Key Points: 
  • CORAL GABLES, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) today reported that it has closed its underwritten public offering of shares of its common stock.
  • The Company sold 10,000,000 shares of its common stock in the offering at a public offering price of $15.00 per share.
  • The Company has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of the Company's common stock at the public offering price, less underwriting discounts.
  • The offering was made only by means of a prospectus and prospectus supplement that formed part of the registration statement.

Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Friday, January 5, 2024

CORAL GABLES, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share, for total gross proceeds of $150,000,000, before deducting underwriting discounts and expenses payable by Catalyst.

Key Points: 
  • CORAL GABLES, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share, for total gross proceeds of $150,000,000, before deducting underwriting discounts and expenses payable by Catalyst.
  • Catalyst has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts.
  • The offering is expected to close on or about January 9, 2024, subject to customary closing conditions.
  • All of the shares in the offering are being sold by Catalyst.

Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Retrieved on: 
Thursday, January 4, 2024

CORAL GABLES, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today that it has commenced an underwritten public offering of $150,000,000 of its common stock.

Key Points: 
  • CORAL GABLES, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today that it has commenced an underwritten public offering of $150,000,000 of its common stock.
  • Catalyst also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts.
  • The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
  • The proposed offering will be made only by means of a prospectus and prospectus supplement that form a part of the registration statement.

Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma

Retrieved on: 
Monday, December 18, 2023

The review period is expected to be approximately a minimum of nine months from the submission date.

Key Points: 
  • The review period is expected to be approximately a minimum of nine months from the submission date.
  • “The NDA submission to the PMDA by our partner DyDo represents a pivotal milestone in our mission to broaden FIRDAPSE’s access as a treatment for LEMS patients in Japan,” stated Patrick J. McEnany, Catalyst’s Chairman and CEO.
  • As we continue to collaborate with our partner during the review process, the submission also triggers an expansion of our territorial rights for the product and a milestone payment to Catalyst.
  • Under the terms of the agreement, Catalyst is eligible to receive a regulatory milestone payment from DyDo upon submission of the NDA to the PMDA.

Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy

Retrieved on: 
Monday, December 18, 2023

In addition, patients who switched from a standard of care corticosteroid to AGAMREE maintained the efficacy benefit while recovering their growth and bone health.

Key Points: 
  • In addition, patients who switched from a standard of care corticosteroid to AGAMREE maintained the efficacy benefit while recovering their growth and bone health.
  • Santhera will continue to collect data to further characterize the long-term effectiveness and the broader safety differentiation of vamorolone.
  • Santhera announced on October 27, 2023 that the FDA approved AGAMREE oral suspension 40 mg/ml in the United States for the treatment of DMD in patients 2 years of age and older.
  • Catalyst Pharmaceuticals holds an exclusive license for AGAMREE in North America and plans to launch the product in the U.S. in Q1-2024.

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies

Retrieved on: 
Tuesday, December 5, 2023

CORAL GABLES, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2024.

Key Points: 
  • CORAL GABLES, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2024.
  • Catalyst has ranked an impressive 4th out of 100 companies on this prestigious list, which recognizes small-cap companies that have demonstrated positive sales growth over the last twelve months.
  • "We are very honored to be recognized among the top companies in the Forbes 2024 Most Successful Small-Cap Companies.
  • Forbes used data from FactSet to compile its annual list of America’s Most Successful Small-Cap Companies; all data was as of November 3, 2023.